Why Are People Talking About Investing in IONS?

By Emilio Sanchez • Wednesday, September 13 10:13 • Permanent Link

More and more people are talking about Ionis Pharmaceuticals over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $42.74? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Ionis Pharmaceuticals has moved -10.0% over the last year, and the S&P 500 logged a change of 14.0%
IONS has an average analyst rating of buy and is -13.88% away from its mean target price of $49.63 per share
Its trailing earnings per share (EPS) is $-2.29
Ionis Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -18.7 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-3.59 and its forward P/E ratio is -11.9
The company has a Price to Book (P/B) ratio of 14.28 in contrast to the S&P 500's average ratio of 2.95
Ionis Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $-269335264, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.